CAS 118353-05-2: Carbovir

Applications A nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) caused mitochondrial toxicity in human hepatoma carcinoma cell. References Suo, Z., et al.: J. Biol. Chem., 273, 27250 (1998), Ray, A., et al.: Antimicrob. Agents Chemother., 48, 1089 (2004), Lynx, M., et al.: Biochem. Pharmacol., 71, 1342 (2006),

Carbovir is a nucleoside reverse transcriptase inhibitor (NRTI), which is derived from carbocyclic nucleosides. Its mode of action involves the selective inhibition of the reverse transcriptase enzyme, an essential component in the replication cycle of retroviruses, such as HIV. By incorporating into the viral DNA chain during synthesis, Carbovir effectively halts chain elongation, thereby impeding the virus's ability to proliferate. Carbovir's primary use is in antiretroviral therapy, particularly in the treatment of HIV infection. It is utilized as part of combination therapy to enhance efficacy and reduce the likelihood of resistance development. This compound is significant in the development of therapeutic strategies aimed at managing viral load and improving the quality of life in individuals affected by HIV. Research continues to explore Carbovir's potential applications and efficacy against other retroviruses, underpinning its role in the broader context of antiviral pharmacology.